摘要
心房颤动(房颤)是临床实践中最常见的持续性心律失常,其显著增加人群发生心力衰竭和缺血性卒中的风险.随着人口老龄化程度加剧和慢性心脏疾病患者的生存状况得到改善,目前房颤的患病率有逐年增高的趋势.房颤的治疗策略包括心率控制和节律控制,以及预防血栓形成.迄今为止,房颤的管理是选择心率控制还是节律控制一直是争论的焦点.
出处
《中国医刊》
CAS
2014年第1期4-6,共3页
Chinese Journal of Medicine
参考文献10
-
1American College of Cardiology Foundation, American Heart Associ- ation, European Society of Cardiology, et al. Management of patients with atrial fibrillation ( compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the Ameri- can College of Cardiology/American Heart Association Task Force on practice guidelines [J]. Circulation, 2013, 127:1916-1926.
-
2Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation [ J ]. N Engl J Med, 2010, 362:1363-1373.
-
3European Heart Rhythm Association, European Association for Car- dio-Thoracie Surgery, Camm AJ, et al. Guidelines for the manage- ment of atrial fibrillation : the Task Force for the Management of Atri- al Fibrillation of the European Society of Cardiology ( ESC ) [ J ]. Eur Heart J, 2010, 31:2369-2429.
-
4Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/ HRS focused update on the management of patients with atrial fibril- lation (update on dabigutran) : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines [ J]. J Am Coil Cardiol, 2011,57:1330-1337.
-
5Groenveld HF, Tijssen JG, Crijns HJ, et al. Rate control efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control: data from RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation) [ J ]. J Am Coil Cardiol, 2013, 61:741-748.
-
6Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation : an up- date of the 2010 ESC Guidelines for the management of atrial fibrilla- tion. Developed with the special contribution of the European Heart Rhythm Association [ J]. Eur Heart J, 2012, 33:2719-2747.
-
7Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedar- one on cardiovascular events in atria/fibrillation [ J ]. N Engl J Med, 2009, 360:668-678.
-
8Connolly SJ, Camm A J, Halperin JL, et al. Dronedarone in high-risk per- manent atrial fibrillation [J]. N Engl J Med, 2011, 365:2268-2276.
-
9Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate con- trol and rhythm control in patients with atrial fibrillation [ J ]. N Engl J Med, 2002, 347:1825-1833.
-
10Chatterjee S, Sardar P, Lichstein E, et al. Pharmacologic rate ver- sus rhythm-control strategies in atrial fibrillation: an updated com- prehensive review and meta-analysis [ J]. Pacing Clin Electrophysi- ol. 2013. 36:122-133.
同被引文献70
-
1杨志宏,洪梅,秦永文.非瓣膜性房颤患者血栓性脑卒中的预防[J].国外医学(心血管疾病分册),2005,32(1):1-3. 被引量:14
-
2胡大一,孙艺红.心房颤动的流行病学和治疗现状[J].中华全科医师杂志,2006,5(1):5-7. 被引量:85
-
3王云书.C反应蛋白升高与心房颤动关系的探讨[J].中华全科医师杂志,2006,5(9):565-566. 被引量:3
-
4心房颤动抗栓研究协作组,胡大一,孙艺红,张鹤萍,姜立清.华法林对非瓣膜病心房颤动抗栓的安全性和有效性研究[J].中华内科杂志,2006,45(10):800-803. 被引量:64
-
5Wong CX, Lau DH, Sanders P. Atrial fibrillation epidemic and hospitalizations: how to turn the rising tide [J ]. Circulation, 2014,129(23) :2361-2363.
-
6Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke:a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe[J]. Chest,2012,142(6) : 1489-1498.
-
7Romero I, Nedios S, Kriatselis C. Diagnosis and management of atrial fibrillation: an overview[J]. Cardiovasc Ther, 2014, 32(5) : 242-252.
-
8Calkins H, Kuck KH, Cappato R, et al. 2012HRS/EHRA/ ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design [J]. Europace,2012,33(2) : 171-257.
-
9Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial [J]. JAMA,2014,312(19) : 1988-1998.
-
10Pedersen OD, Abildstrom SZ, Ottesen MM, et al. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction[J]. Eur Heart J,2006,27(3) :290-295.
引证文献4
-
1王捷.老年患者心房颤动的临床特点[J].中国老年保健医学,2014,12(5):57-59. 被引量:3
-
2王浩宇,衣欣,胡奉环.华法林在高龄房颤患者中不同抗凝强度的疗效及安全性分析[J].中国医刊,2015,50(8):34-35. 被引量:6
-
3齐书英,袁晓红.器质性心脏病心房颤动患者的药物治疗[J].临床荟萃,2016,31(1):27-29. 被引量:1
-
4李晓红,胡亚民,刘丽娜,吴萍,李晓岚,刘海霞.心房颤动患者血清炎症指标的意义及其对合并左心耳血栓形成的预测价值[J].中国中西医结合急救杂志,2018,25(3):278-282. 被引量:12
二级引证文献22
-
1李辉,琚媛媛.BNP与Hcy水平联合检测对非瓣膜性心房颤动患者左心房血栓形成的价值[J].医药论坛杂志,2021,42(23):129-132.
-
2陈曦,丁中,杨晓双,王艳昕.经胸心超、经食道心超及血清学指标检测房颤患者左心耳血栓的临床研究[J].湖南师范大学学报(医学版),2021,18(4):187-190. 被引量:4
-
3孟素芳.慢性心房颤动伴晕厥患者心电图特点分析[J].医药论坛杂志,2015,36(11):49-50. 被引量:2
-
4李莲静,刘健,蒋卫民.105例非瓣膜性心房颤动患者门诊抗凝治疗调查[J].中华全科医学,2015,13(12):2014-2017. 被引量:8
-
5姚璐,张薇,田国祥,夏常泉,武云涛,王晓兵,李娟.达比加群酯应用于高龄老年非瓣膜性心房纤颤患者中的安全性评价[J].中国循证心血管医学杂志,2016,8(5):547-549. 被引量:16
-
6唐银辉,黄熙媛.华法林长期治疗伴血栓形成史高龄房颤患者32例临床观察[J].中西医结合心血管病电子杂志,2016,4(12):65-66. 被引量:1
-
7井华,杨金敏.临床药师参与1例晚期胃癌多学科讨论的实践[J].临床医药文献电子杂志,2016,3(41):8268-8268. 被引量:1
-
8王冬,杨新,贾邢倩.慢室率心房颤动的动态心电图特征及发生机制的探讨[J].实用心电学杂志,2017,26(2):116-118. 被引量:4
-
9王吉.快速心律失常药物治疗的临床研究进展[J].心血管病防治知识(学术版),2018,8(5):92-94.
-
10冯薇,陈力.老年心房颤动患者应用华法林的出血风险及预防分析[J].中国处方药,2018,16(4):1-2.
-
1黄永麟,王家宏.药物治疗心房颤动的近代处理原则[J].中国心脏起搏与心电生理杂志,2006,20(3):201-204. 被引量:5
-
2王黎霞.胺碘酮治疗阵发性房颤的疗效观察[J].海峡药学,2011,23(8):128-129. 被引量:3
-
3陈柯萍.心房颤动的治疗及临床用药问答(2)[J].中国社区医师,2006,22(15):20-20.
-
4曹佳齐,任建英.027持续性房颤病人控制心率比节律更经济:心率控制与电复律的比较(RACE)研究[英]/HagensVE…//EurHeart J[J].国外医学(心血管疾病分册),2005,32(2):125-125.
-
5许俊堂.房颤者莫忘抗血栓[J].药物与人,2009(1):22-22.
-
6余国膺.上世纪90年代心房颤动治疗的改变[J].中国介入心脏病学杂志,2004,12(4):252-252.
-
7佟绍师,夏福荣.美托洛尔致过敏反应1例[J].中华保健医学杂志,2009,11(1):11-11. 被引量:4
-
8唐利,向毅,杜潇,杨泉.抗血栓药物临床应用研究进展[J].心血管病学进展,2016,37(6):672-677. 被引量:15
-
9魏永燕,汤日波.达比加群酯在心房颤动抗凝治疗中的研究进展[J].实用医学杂志,2013,29(5):683-685. 被引量:31
-
10李小鹰.老年房颤患者应规范华法林的应用——实现抗凝和降低出血风险双获益[J].中国社区医师,2010,26(41):8-8. 被引量:5